News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY) Breast Cancer Drug Gets FDA Priority Review


2/8/2012 8:12:29 AM

Roche Holding AG Wednesday said the U.S. Food and Drug Administration has accepted the company's Biologics License Application for pertuzumab and granted Priority Review. MAIN FACTS: - The proposed indication is pertuzumab in combination with Herceptin (trastuzumab) and docetaxel chemotherapy for people with HER2-positive metastatic or locally recurrent, unresectable breast cancer, who have not received previous treatment or whose disease has relapsed after adjuvant therapy.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES